Here’s the MOA… not too shabby
”• Results from three randomized controlled trials in class II/III HFrEF and in end-stage HFrEF with left ventricular assist devices (LVADs) support the idea of a common mechanism of action (MOA) by which rexlemestrocel-L reverses inflammation-related endothelial dysfunction and reduces adverse clinical outcomes across the spectrum of HFrEF patients .”
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-3
-
- There are more pages in this discussion • 297 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.000(0.00%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | $1.02 | $1.047M | 1.008M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 13563 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 33946 | 8 |
View Market Depth
| Last trade - 10.13am 24/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |